Novo’s complaint, filed June 24 in the US District Court for the District of Delaware, expands its legal fight over patents related to Saxenda, many of which it’s also asserting in pending cases over its blockbuster diabetes drug Ozempic.
The drug’s main patent, which covers Saxenda’s active ingredient and methods of making and using it, isn’t part of the Orbicular suit. It expires in February 2023, …
